GlobeNewswire

Mascot Bidco Oy Has Gained Title to All the Shares in Amer Sports Corporation and the Shares Have Been Delisted from Nasdaq Helsinki

Share

Amer Sports Corporation
STOCK EXCHANGE RELEASE
September 5, 2019 at 9:00 a.m. (EEST)

Mascot Bidco Oy Has Gained Title to All the Shares in Amer Sports Corporation and the Shares Have Been Delisted from Nasdaq Helsinki

Mascot Bidco Oy (“Mascot”) has on 4 September 2019 placed security approved by the Arbitral Tribunal and thus gained title to all the shares in Amer Sports Corporation (“Amer Sports”) in accordance with Chapter 18, Section 6 of the Finnish Companies Act. After the security has been placed and the title to the shares transferred, the minority shareholders of Amer Sports being parties to the redemption proceedings are entitled to receive only the redemption price and the interest payable thereon.

Upon application by Amer Sports, Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) has on 23 August 2019 decided that Amer Sports shares will be delisted from the Official List of Nasdaq Helsinki after Mascot has gained title to all the shares in Amer Sports in the redemption proceedings in accordance with the Finnish Companies Act. The quotation of the Amer Sports shares on Nasdaq Helsinki ceased on 4 September 2019 in accordance with a separate release published by Nasdaq Helsinki.

After the delisting has taken place, Amer Sports is not subject to the periodic reporting obligation set out in the Securities Market Act and will thereby not publish a half year report or other periodic financial reporting from the ongoing or future reporting periods.

For further information, please contact:
Samppa Seppälä, Head of Corporate Communications and IR
Amer Sports Corporation
Tel. +358 50 568 0533

DISTRIBUTION
Nasdaq Helsinki
Main media
www.amersports.com

AMER SPORTS
Amer Sports (www.amersports.com) is a sporting goods company with internationally recognized brands including Salomon, Arc’teryx, Peak Performance, Atomic, Suunto, Wilson and Precor. The company’s technically advanced sports equipment, footwear, and apparel improve performance and increase the enjoyment of sports and outdoor activities. The Group’s business is balanced by its broad portfolio of sports and products and a presence in all major markets.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Participation Notification by Blackrock Inc.21.9.2020 08:30:00 CESTPress release

Participation notification by Blackrock Inc. Brussels, September 21, 2020, 08:30 CEST - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalSeptember 15, 20203.05%0.11%3.16%September 17, 20202.88%0.16%3.14% The latest notification, dated September 18, 2020, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: September 17, 2020Threshold of direct voting rights crossed: 3% downwardsDenominator: 105,876,416Additional information: The disclosure ob

Vallourec Announces Required Consents Received in its Consent Solicitation Relating to Certain of its Notes21.9.2020 08:00:00 CESTPress release

Boulogne-Billancourt (France), 21 September 2020 – As announced on 1 September 2020, Vallourec launched a consent solicitation on 2 September 2020 seeking the consent of the holders of its US law governed bonds due in 2022 (Code: XS1700480160) and in 2023 (Code: XS1807435026). The purpose of this consent solicitation was to obtain the consent, with the required majority of each series of such bonds, to effect certain waivers in order to permit Vallourec, if it wishes to do so, to request the appointment of a mandataire ad hoc without such action constituting an event of default under the indentures governing such bonds. Vallourec announces today that on 18 September 2020 it has received the requisite consents under each series of bonds and that it intends to request, as soon as practicable, the appointment of a mandataire ad hoc. Vallourec has also obtained the authorizations from its banks in accordance with the terms of the relevant revolving credit agreements, to engage discussions

Volta Finance Limited - Dividend Declaration21.9.2020 08:00:00 CESTPress release

Volta FinanceLimited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 21 September 2020 Volta Finance Limited ("the Company") hereby announces a third interim dividend for the financial year commencing 1 August 2019. The Company announces that it has declared a quarterly interim dividend of €0.11 per share payable on 29 October 2020 amounting to approximately €4.24 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 1 October 2020 with a record date of 2 October 2020. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Comput

Nokia CEO signs UN pledge calling for renewed global co-operation21.9.2020 07:00:00 CESTPress release

Press Release Nokia President and CEO, Pekka Lundmark signs a joint Statement that will be handed to the UN Secretary General General to mark the 75th anniversary of the United NationsThe Statement commits more than 1,000 leaders to: ethical leadership and good governance; invest in addressing inequalities and injustice; promote equality and respect human rights 21 September 2020 Espoo, Finland – Nokia President and CEO, Pekka Lundmark has signed a joint UN Statement, UNITED IN THE BUSINESS OF A BETTER WORLD which will be presented to the UN Secretary General as part of celebration of the 75th anniversary of the United Nations. The Statement, signed by more than 1,000 global CEOs, says that at time of unprecedented disruption and global transformation, international cooperation must be mobilized across borders, sectors and generations. CEOs signing the statement commit to ethical leadership and good governance, to invest in addressing inequalities and injustice, and to partner with the

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation19.9.2020 16:25:00 CESTPress release

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3 Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only trea

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma19.9.2020 16:20:00 CESTPress release

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the long